# Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

> **NCT01404585** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 123 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** BMS-817399
- **DRUG:** BMS-817399

## Key facts

- **NCT ID:** NCT01404585
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01404585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01404585, "Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01404585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*